The Japanese development agency is stepping beyond traditional grants, joining VCs and corporate giants to finance the expansion of a Ghanaian "phygital" healthcare provider.
Simon Hazell returns to the CEO seat at Bioshroom, betting on high-margin wellness over commodity protein after energy crises and strategic missteps shuttered his previous agritech venture.
In a year when "following the herd" described most African venture activity, these outlier deals stand out for actually taking risk. Which is, theoretically, what venture capital is supposed to do.
